Known targets — ChEMBL curated mechanism
PRKAA1PRKAA2PRKAB1PRKAB2PRKAG1PRKAG2PRKAG3
The experimentally established mechanism targets of Acadesine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.77 |
| ▸ | HTT | P42858 | 2/20 | 0.77 |
| ▸ | BLM | P54132 | 2/20 | 0.77 |
| ▸ | TSHR | P16473 | 2/20 | 0.77 |
| ▸ | GAA | P10253 | 1/20 | 0.77 |
| ▸ | FBP1 | P09467 | 1/20 | 0.69 |
| ▸ | ATIC | P31939 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 5/20 | 0.60 |
| ▸ | THPO | P40225 | 2/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.60 |
| ▸ | GMNN | O75496 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.60 |
| ▸ | MTOR | P42345 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acadesine SCHEMBL219336 | 1.00 | KDM4E (1.00) | KDM4ETP53TDP1MAPTSMN1; SMN2 | |
| Acadesine SCHEMBL28745421 | 1.00 | KDM4E (1.00) | KDM4ETP53TDP1MAPTSMN1; SMN2 | |
| Acadesine SCHEMBL2619704 | 1.00 | KDM4E (1.00) | KDM4ETP53TDP1MAPTSMN1; SMN2 | |
| Acadesine SCHEMBL2394079 | 1.00 | KDM4E (1.00) | KDM4ETP53TDP1MAPTSMN1; SMN2 | |
| Acadesine SCHEMBL10017743 | 1.00 | KDM4E (1.00) | KDM4ETP53TDP1MAPTSMN1; SMN2 | |
| Acadesine SCHEMBL6113798 | 1.00 | KDM4E (1.00) | KDM4ETP53TDP1MAPTSMN1; SMN2 | |
| Acadesine SCHEMBL5053863 | 1.00 | KDM4E (1.00) | KDM4ETP53TDP1MAPTSMN1; SMN2 | |
| Acadesine SCHEMBL14520658 | 1.00 | KDM4E (1.00) | KDM4ETP53TDP1MAPTSMN1; SMN2 | |
| Acadesine SCHEMBL2631614 | 1.00 | KDM4E (1.00) | KDM4ETP53TDP1MAPTSMN1; SMN2 | |
| Acadesine SCHEMBL8722270 | 0.95 | KDM4E (0.91) | KDM4ETP53TDP1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6642206-B2 | Useful in treating a wide variety of diseases including infections, infestations, neoplasms and autoimmune diseases | ICN PHARMACEUTICALS, INC. | 2003-11-04 | — | — | US | disclosed |
| US-6573248-B2 | Therapeutic agent for use in the treatment of tumors, infections, infestation and autoimmune disease | ICN PHARMACEUTICALS, INC. | 2003-06-03 | — | — | US | disclosed |
| US-6552183-B1 | Moncyclic L-nucleosides analogs | ICN PHARMACEUTICALS, INC. | 2003-04-22 | — | — | US | disclosed |
| EP-1302474-A1 | Monocyclic L-nucleosides, analogs and uses thereof | Ribapharm, Inc. (US) | 2003-04-16 | — | — | EP | disclosed |
| US-20030018186-A1 | Monocyclic L-nucleosides, analogs and uses thereof | BAUSCH HEALTH COMPANIES INC. (CA) | 2003-01-23 | — | — | US | disclosed |
| EP-1254911-A1 | Monocyclic L-nucleosides, analogs and uses thereof | ICN Pharmaceuticals, Inc. (US) | 2002-11-06 | — | — | EP | disclosed |
| US-20020095033-A1 | Monocyclic L-nucleosides, analogs and uses thereof | ICN PHARMACEUTICALS, INC. | 2002-07-18 | — | — | US | disclosed |
| EP-1027359-A4 | MONOCYCLIC L-NUCLEOSIDES, ANALOGS AND USES THEREOF | ICN PHARMACEUTICALS (US) | 2001-07-25 | — | — | EP | disclosed |
| US-6130326-A | Monocyclic L-Nucleosides, analogs and uses thereof | ICN PHARMACEUTICALS, INC. (US) | 2000-10-10 | — | — | US | disclosed |
| EP-1027359-A2 | MONOCYCLIC L-NUCLEOSIDES, ANALOGS AND USES THEREOF | ICN Pharmaceuticals, Inc. (US) | 2000-08-16 | — | — | EP | disclosed |
| WO-1998016186-A2 | MONOCYCLIC L-NUCLEOSIDES, ANALOGS AND USES THEREOF | ICN PHARMACEUTICALS, INC. (US) | 1998-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018186-A1 | Monocyclic L-nucleosides, analogs and uses thereof | PNP, TYMP, SLC29A1 | KDM4E 1775/4885TP53 1942/4885TDP1 985/4885 |
| US-20020095033-A1 | Monocyclic L-nucleosides, analogs and uses thereof | PNP, TYMP, SLC29A1 | KDM4E 1775/4885TP53 1942/4885TDP1 985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.